Abstract
Allelic deletions of chromosome 18q are reported to be common in prostate and colorectal cancers, suggesting that one or more tumor suppressor genes on 18q are involved in the genesis of these neoplasms. The DPC4 gene, a recently identified candidate tumor suppressor in 18q21, was examined for evidence of inactivation in prostatic carcinomas, and results compared to those of a parallel analysis of colorectal carcinomas, for which DPC4 mutation has been reported in ∼10% of cases. In this study, only three (10%) of 29 informative primary prostate cancers showed allelic loss of chromosome 18q21 markers, and no point mutations or deletions of DPC4 were detected in the complete set of 45 primary or metastatic cases. In contrast, five (56%) of nine primary colorectal tumors displayed allelic loss of 18q markers and in one of these a somatically acquired G→T missense mutation was found in exon 1. Of twelve colorectal tumor cell lines, one showed a G→C missense mutation in exon 8 and two had partial homozygous deletions that would likely abrogate gene function. These data suggest that DPC4 is rarely if ever mutated during prostatic oncogenesis, whereas inactivation of this gene may contribute to the genesis of a subset of colorectal carcinomas.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 50 print issues and online access
$259.00 per year
only $5.18 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
MacGrogan, D., Pegram, M., Slamon, D. et al. Comparative mutational analysis of DPC4 (Smad4) in prostatic and colorectal carcinomas. Oncogene 15, 1111–1114 (1997). https://doi.org/10.1038/sj.onc.1201232
Received:
Revised:
Accepted:
Issue Date:
DOI: https://doi.org/10.1038/sj.onc.1201232
Keywords
This article is cited by
-
Bromodomain and extra-terminal motif (BET) inhibition is synthetic lethal with loss of SMAD4 in colorectal cancer cells via restoring the loss of MYC repression
Oncogene (2021)
-
SMAD2 rs4940086 heterozygosity increases the risk of cervical cancer development among the women in Bangladesh
Molecular Biology Reports (2020)
-
Evaluation of protein biomarkers of prostate cancer aggressiveness
BMC Cancer (2014)
-
Role of SMAD4 in the mechanism of valproic acid’s inhibitory effect on prostate cancer cell invasiveness
International Urology and Nephrology (2014)
-
The prognostic value of Smad4 mRNA in patients with prostate cancer
Tumor Biology (2014)